Genetic variants of antioxidant and xenobiotic metabolizing enzymes and their association with prostate cancer: A meta-analysis and functional in silico analysis.

Beatriz Álvarez-González, Patricia Porras-Quesada, Verónica Arenas-Rodríguez, Alba Tamayo-Gómez, Fernando Vázquez-Alonso, Luis Javier Martínez-González, Antonio F Hernández, María Jesús Álvarez-Cubero

Journal: The Science of the total environment 2023;898():165530

PMID: 37453710

Abstract

The development and progression of prostate cancer (PCa) depends on complex interactions between genetic, environmental and dietary factors that modulate the carcinogenesis process. Interactions between chemical exposures and genetic polymorphisms in genes encoding xenobiotic metabolizing enzymes (XME), antioxidant enzymes and DNA repair enzymes have been reported as the main drivers of cancer. Thus, a better understanding of the causal risk factors for PCa will provide avenues to identify men at increased risk and will contribute to develop effective detection and prevention methods. We performed a meta-analysis on 17,518 cases and 42,507 controls obtained from 42 studies to determine whether seven SNPs and one CNV pertaining to oxidative stress, xenobiotic detoxification and DNA repair enzymes are associated with the risk of PCa (GPX1 (rs1050450), XRCC1 (rs25487), PON1 (rs662), SOD2 (rs4880), CAT (rs1001179), GSTP1 (rs1695) and CNV GSTM1). A significant increased risk of PCa was found for SOD2 (rs4880) OR 1.08; 95%CI 1.01-1.15, CAT (rs1001179) OR 1.39; 95%CI 1.17-1.66, PON1 (rs662) OR 1.17; 95%CI 1.01-1.35, GSTP1 (rs1695) OR 1.20; 95%CI 1.05-1.38 and GSTM1 (dual null vs. functional genotype) OR 1.34; 95%CI 1.10-1.64. The meta-analysis showed that the CNV GSTM1, and the SNPs GSTP1 (rs1695) and CAT (rs1001179) are strongly associated with a greater risk of PCa and, to a lesser extent, the genetic variants SOD2 (rs4880) and PON1 (rs662). Although several antioxidant enzymes and XME play an important role in the PCa development, other risk factors such as chemical exposures should also be considered to gain insight on PCa risk. The functional in silico analysis showed that the genetic variants studied had no clinical implication regarding malignancy, except for GPX1 (rs1050450) SNP.

Copyright © 2023. Published by Elsevier B.V.

Address: University of Granada, Legal Medicine and Toxicology Department, Faculty of Medicine, PTS, Granada, Spain; GENYO, Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, PTS Granada, Granada, Spain.; GENYO, Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, PTS Granada, Granada, Spain; University of Granada, Department of Biochemistry and Molecular Biology III and Immunology, Faculty of Medicine, PTS, Granada, Spain.; Urology Department, University Hospital Virgen de las Nieves, Av. de las Fuerzas Armadas 2, Granada, Spain.; GENYO, Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, PTS Granada, Granada, Spain. Electronic address: [email protected].; University of Granada, Legal Medicine and Toxicology Department, Faculty of Medicine, PTS, Granada, Spain; Biosanitary Research Institute, ibs.GRANADA, Granada, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Spain.; GENYO, Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, PTS Granada, Granada, Spain; University of Granada, Department of Biochemistry and Molecular Biology III and Immunology, Faculty of Medicine, PTS, Granada, Spain; Biosanitary Research Institute, ibs.GRANADA, Granada, Spain.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.